华体Huati品牌怎么样 申请店铺

我要投票 华体Huati在照明灯具行业中的票数:598 更新时间:2025-09-11
华体Huati是哪个国家的品牌?「华体Huati」是 四川华体照明科技股份有限公司 旗下著名品牌。该品牌发源于四川省成都市,由创始人梁熹在2004-05-21期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力华体Huati品牌出海!将品牌入驻外推网,定制华体Huati品牌推广信息,可以显著提高华体Huati产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

华体Huati怎么样

四川华体照明科技股份有限公司,知名照明灯具品牌,集户外灯具等产品的设计、生产、销售、安装一条龙服务的大型企业


开拓之光,怀揣梦想

四川华体照明科技股份有限公司(股票简称:华体科技 股票代码:603679)成立于2004年,总部位于享有“天府之国”美誉之称的成都双流西南航空港经济开发区,是一家集照明方案设计、产品研发制造、工程项目实施、物联网智能管理维护四大业务板块为一体的户外照明企业。公司占地面积160余亩,拥有员工800余人,为中国较大的户外道路照明企业。公司主要优势业务包括智慧路灯、文化照明产品、LED户外大功率照明产品、城市景观亮化工程及公共设施。经过多年的历练和沉淀,探索与发展,公司完成了从单一生产向全产业链覆盖的蜕变。

华体之光,明耀四方

目前公司销售网络遍布全国20多个省市区,形成了辐射全国的强势销售网络。公司产品以“规模大、配套齐、技术性能优、节能环保、性价比高”的竞争优势享誉海内外市场,现已遍布国内并远销欧美。2016年,公司实现销售收入 4.08 亿,上缴税收4000多万,在我国城市户外照明行业销售额、利税总额、品牌效益等综合指标中稳居前列,同时,主营产品全国范围内市场综合占有率持续增长。

一手抓设计,一手抓科技

心怀天下、志存高远的华体照明人,秉承“遵道贵德,精诚至善” 的核心价值观,以专业的团队,优质的服务,坚定的信心,赢得国内外众多客户的信赖。智慧的华体人将不忘初心、砥砺前行,这必将铸就属于我们的辉煌,亦将迎来更加美好的明天!


Sichuan huati Lighting Technology Co., Ltd., a well-known brand of lighting fixtures, is a large-scale enterprise integrating the design, production, sales and installation of outdoor lighting products. Sichuan huati Lighting Technology Co., Ltd. (Stock Code: 603679 for short) was founded in 2004 with its headquarters in the country of abundance Chengdu Shuangliu Southwest Airport Economic Development Zone is an outdoor lighting enterprise integrating four business sectors, i.e. lighting scheme design, product R & D and manufacturing, engineering project implementation, intelligent management and maintenance of the Internet of things. The company covers an area of more than 160 Mu and has more than 800 employees. It is a large outdoor road lighting enterprise in China. The company's main advantages include smart street lights, cultural lighting products, LED outdoor high-power lighting products, urban landscape lighting projects and public facilities. After years of experience and precipitation, exploration and development, the company has completed the transformation from single production to full industrial chain coverage. At present, the company's sales network covers more than 20 provinces and cities in China, forming a strong sales network radiating across the country. The company's products are well-known at home and abroad for their competitive advantages of "large scale, complete set, excellent technical performance, energy conservation and environmental protection, and high cost performance". Now they are all over China and exported to Europe and America. In 2016, the company achieved a sales revenue of 408 million yuan and paid over 40 million taxes. It is firmly in the forefront of comprehensive indicators such as sales volume, total profits and taxes, brand benefits, etc. in China's urban outdoor lighting industry. At the same time, the comprehensive market share of its main products in the whole country continues to grow. We should pay attention to design, technology, and the world-wide, ambitious Chinese lighting people, adhere to the core values of "follow the way, be sincere and good", and win the trust of many customers at home and abroad with professional team, high-quality service and firm confidence. The wise Chinese people will not forget their original intention and forge ahead, which will surely create our brilliance and usher in a better tomorrow!

本文链接: https://brand.waitui.com/9a8503343.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

阿里巴巴获南向资金净买入37.3亿港元

南向资金今日净买入189.89亿港元。其中阿里巴巴-W、信达生物、中芯国际净买入额位列前三,分别获净买入37.3亿港元、9.57亿港元、9.32亿港元。净卖出方面,腾讯控股、康方生物、美团-W分别遭净卖出11.51亿港元、3.9亿港元、0.97亿港元。(第一财经)

2小时前

深圳麦科田生物医疗技术股份有限公司向港交所提交上市申请书

36氪获悉,深圳麦科田生物医疗技术股份有限公司向港交所提交上市申请书,联席保荐人为摩根士丹利、华泰国际。

2小时前

芯原股份:拟以发行股份及支付现金方式购买芯来智融股权,股票复牌

36氪获悉,芯原股份发布公告,公司拟以发行股份及支付现金的方式购买芯来智融半导体科技(上海)有限公司股权并募集配套资金。2025年9月11日,公司召开第三届董事会第三次会议,审议通过《关于公司本次发行股份及支付现金购买资产并募集配套资金方案的议案》《关于公司本次发行股份及支付现金购买资产并募集配套资金预案及其摘要的议案》等与本次交易相关的议案。公司股票将于2025年9月12日开市起复牌。

2小时前

澳新银行首席风险官Kevin Corbally卸任

澳新银行9月11日宣布,首席风险官Kevin Corbally卸任,但将继续留在该行。根据声明,Corbally将成为资本管理机构的董事总经理,并向该公司的机构主管Mark Whelan汇报工作。(界面)

2小时前

智翔金泰:泰利奇拜单抗注射液新药上市申请获受理

36氪获悉,智翔金泰发布公告,近日,公司的泰利奇拜单抗注射液(GR1802注射液)用于成人中、重度特应性皮炎适应症III期临床试验达到了主要终点指标,公司向国家药品监督管理局(NMPA)药品审评中心(CDE)提交了该适应症的新药上市申请并获得受理。截至本公告披露日,泰利奇拜单抗注射液(GR1802注射液)同靶点药物仅有两款在国内获批上市。

2小时前

本页详细列出关于华体Huati的品牌信息,含品牌所属公司介绍,华体Huati所处行业的品牌地位及优势。
咨询